Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trimetazidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.97 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.97 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.54 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.54 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.54 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.54 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.54 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.54 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.54 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.54 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.54 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.54 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimetazidine SCHEMBL2901538 | 1.00 | APOBEC3A (1.00) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 | |
| Trimetazidine SCHEMBL348591 | 1.00 | APOBEC3A (1.00) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 | |
| Trimetazidine SCHEMBL29605009 | 1.00 | APOBEC3A (1.00) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 | |
| Trimetazidine SCHEMBL29677959 | 1.00 | APOBEC3A (1.00) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 | |
| Trimetazidine SCHEMBL29375563 | 0.98 | CHRM2 (1.00) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 | |
| Trimetazidine SCHEMBL11846840 | 0.98 | CHRM2 (1.00) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 | |
| Trimetazidine SCHEMBL230374 | 0.98 | CHRM2 (1.00) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 | |
| Trimetazidine SCHEMBL15302482 | 0.97 | CHRM2 (0.97) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 | |
| Trimetazidine SCHEMBL3896420 | 0.97 | CHRM2 (0.97) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 | |
| Trimetazidine SCHEMBL12485382 | 0.95 | CHRM2 (0.94) | APOBEC3ACTDSP1APOBEC3GCHRM2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352504-A1 | LEVOCARNITINE AND TRIMETAZIDINE BILAYER TABLET AND PREPARATION METHOD THEREOF | CHANGZHOU HIGH TECH INDUSTRIAL DEVELOPMENT ZONE 3D INDUSTRIAL TECH RES INSTITUTE CO LTD (CN) | 2025-11-20 | — | — | US | claimed |
| CN-118420566-B | Preparation method of high-purity trimetazidine hydrochloride | 海南锦麟医药科技有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118777471-A | Trimetazidine hydrochloride sustained release tablet quality detection device | 湖南明瑞制药股份有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118420566-A | Preparation method of high-purity trimetazidine hydrochloride | 海南锦麟医药科技有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240139205-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | UNIVERSITE DE LAUSANNE (CH) | 2024-05-02 | — | — | US | claimed |
| CN-117398354-A | Levocarnitine trimetazidine double-layer tablet | 常州高新技术产业开发区三维工业技术研究所有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-116919923-A | Trimetazidine hydrochloride oral film-dissolving agent | 北京新领先医药科技发展有限公司 | 2023-10-24 | — | — | CN | claimed |
| EP-4114378-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | Université de Lausanne (CH) | 2023-01-11 | — | — | EP | claimed |
| CN-218011101-U | A wiped film evaporator equipment for preparing trimetazidine dihydrochloride | 苏州敬业医药化工有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-110882229-B | Trimetazidine hydrochloride single-layer osmotic pump controlled release tablet and preparation method thereof | 中国药科大学 | 2022-10-11 | — | — | CN | claimed |
| EP-1195160-B1 | Sustained release trimetazidine pharmaceutical compositions and a method of their preparation | USV LTD (IN) | 2009-09-16 | — | — | EP | claimed |
| EP-1108424-B1 | Matrix tablet for sustained release of trimetazidine after oral administration | SERVIER LAB (FR) | 2005-06-01 | — | — | EP | claimed |
| CN-1166408-C | Substrate tablet containing trimetazidine capable of long time controlled release after oral application | ɪά��ʵ���� | 2004-09-15 | — | — | CN | claimed |
| EP-1448173-A2 | A PROCESS FOR MANUFACTURE OF A SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING MICROBEADS OF TRIMETAZIDINE DIHYDROCHLORIDE | Themis Laboratories Private Limited (IN) | 2004-08-25 | — | — | EP | claimed |
| WO-2003043610-A2 | A PROCESS FOR MANUFACTURE OF A SUSTAINED RELEASE COMPOSITION CONTAINING MICROBE | THEMIS LABORATORIES PRIVATE LIMITED (IN) | 2003-05-30 | — | — | WO | claimed |
| EP-1195160-A1 | Sustained release trimetazidine pharmaceutical compositions and a method of their preparation | USV Ltd. (IN) | 2002-04-10 | — | — | EP | claimed |
| EP-0613686-B1 | Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the nephrotoxicity of cyclosporin A | ADIR (FR) | 2001-08-16 | — | — | EP | claimed |
| CN-1302663-A | Substrate tablet containing trimetazidine capable of long time controlled release after oral application | ADIR (FR) | 2001-07-11 | — | — | CN | claimed |
| EP-1104673-A1 | A hydrogen carbonate-containing, desintegrating agent-free pharmaceutical composition | Bayer Classics (FR) | 2001-06-06 | — | — | EP | claimed |
| US-4407801-A | HIGH DOSAGE OF 1-(2,3,4-TRIMETHOXYBENZYL)PIPERAZINE AND A DISINTEGRATING AGENT | SCIENCE UNION ET CIE (FR) | 1983-10-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352504-A1 | LEVOCARNITINE AND TRIMETAZIDINE BILAYER TABLET AND PREPARATION METHOD THEREOF | TRIM4, HMGCR, TRIM58 | CHRM2 189/4885OPRK1 2351/4885SLC6A4 1034/4885 |
| US-20240139205-A1 | MODULATORS OF ARALAR FOR TREATING NEUROLOGICAL DISORDERS | CYFIP1, GABARAPL1, GABRR1 | CHRM2 2267/4885OPRK1 547/4885SLC6A4 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.